From: Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset
Information category | Existing variable | New variable | Value label | Variable type | Value categories | Completeness (%) |
---|---|---|---|---|---|---|
Patient | Patient identification number | Â | Randomly generated patient identification number | Numeric | Â | 100Â |
State | Â | State identification | Categorical | [VIC; SA] | 100Â | |
 | Age at diagnosis | Patient’s age at diagnosis, derived from date of birth | Numeric |  | 100 | |
 | Age groups | Ten year age groups, derived from age at diagnosis | Categorical | [<55; 55–65; 66–75; >75] | 100 | |
Date of death | Â | Date of death | Date | Â | NA | |
Postcode of residence | Â | Postcode of residence | Numeric | Â | 97.6 | |
 | SEIFA score | Postcode of residence linked with SEIFA-2011 | Numeric |  | 97.6 | |
 | SEIFA decile | Postcode of Residence linked with SEIFA-2011 | Categorical | [1..10] | 97.6 | |
Diagnosis | Date of diagnosis | Â | Date of diagnosis | Date | Â | 100 |
 | Year of diagnosis | Derived from date of diagnosis | Numeric |  | 100 | |
Diagnosis procedure type | Â | Biopsy type | Categorical | [TRUS; TURP; other] | 96.9 | |
PSA at diagnosis | Â | PSA levels at diagnosis | Numeric | Â | 86.6 | |
Gleason primary score | Â | Biopsy Gleason primary score at diagnosis | Numeric | Â | 92.9 | |
Gleason secondary score | Â | Biopsy Gleason secondary score at diagnosis | Numeric | Â | 92.8 | |
Gleason tertiary score | Â | Biopsy Gleason tertiary score at diagnosis | Numeric | Â | 89.6 | |
Gleason total score | Â | Biopsy Gleason total score at diagnosis | Numeric | Â | 97.5 | |
Biopsy number | Â | Biopsy number to identify multiple biopsies | Numeric | Â | 100 | |
Biopsy type | Â | Biopsy type | Categorical | [TRUS; TURP; TURBT; transperineal biopsy; clinical investigation (e.g. bone scan, CT, MRI); histology of metastatic site (bone biopsy or lymph node biopsy); prostatectomy (simple, diagnostic); other; unknown] | 97.4 | |
Biopsy date | Â | Biopsy date | Date | Â | 100 | |
Total number of cores | Â | Total number of cores taken | Numeric | Â | 78.1 | |
Total number of positive cores | Â | Total number of positive cores | Numeric | Â | 78.1 | |
Gleason primary score | Â | Biopsy Gleason primary score for each biopsy | Numeric | Â | 89.7 | |
Gleason secondary score | Â | Biopsy Gleason secondary score for each biopsy | Numeric | Â | 89.5 | |
Gleason tertiary score | Â | Biopsy Gleason tertiary score for each biopsy | Numeric | Â | NA | |
Gleason total score | Â | Biopsy Gleason total score for each biopsy | Numeric | Â | 93.8 | |
Perineural invasion | Â | Perineural invasion flag | Categorical | [Yes; no] | 100 | |
Lymphovascular invasion | Â | Lymphovascular invasion flag | Categorical | [Yes; no] | 100 | |
T-stage at diagnosis | Â | T-stage at diagnosis | Categorical | [TX (cannot be assessed);T0; T1; T1a; T1b; T1c; T2Â l; T2a; T2b; T2c; T3; T3a; T3b; T4; T4a; T4b] | 53.4 | |
N-stage at diagnosis | Â | N-stage at diagnosis | Categorical | [NX (cannot be assessed); N0; N1; inconclusive] | 63.7 | |
M-stage at diagnosis | Â | M-stage at diagnosis | Categorical | [MX (cannot be assessed); M0; M1a; M1b; M1c; inconclusive] | 63.7 | |
 | NCCN | NCCN stage calculated according to the formula from clinical T-stage, PSA level and Gleason score at diagnosis | Categorical | [Low; intermediate; high; very high; metastatic] | 92.4 | |
Treatment | Treatment type | Â | First treatment type | Categorical | [AA; ADT; Brachytherapy; Chemotherapy; EBRT; HDR; LDR; RALRP; low dose agonists; ORPR other; recent biopsy; WW] | 93Â |
Treatment date | Â | First treatment date | Date | Â | 93 | |
 | Treatment group | Treatment group derived from treatment type | Categorical | [Surgery; radiation therapy; ADT; AS, WW; other; unknown] | 92.8 | |
 | Time to the first treatment | Time (days) to the first treatment, derived from date of diagnosis and date of first treatment | Numeric |  | 72.5 | |
Radiotherapy | Â | Â | Â | Â | Â | NÂ =Â 38,052 |
 | Radiotherapy type |  | Type of radiotherapy received, can be multiple treatments | Categorical | [EBRT radical; EBRT palliative; brachytherapy] | (100) |
Start radiotherapy date | Â | Date of start radiotherapy | Date | Â | 100 | |
Dose | Â | Dose (amount) of radiotherapy | Numeric | Â | 32.9 | |
Fractions | Â | Fractions of radiotherapy given | Numeric | Â | 29.7 | |
Dose rate | Â | Type of dose of radiotherapy | Categorical | [LDR; HDR] | 21.7 | |
Surgery | Â | Â | Â | Â | Â | NÂ =Â 5874 |
 | Operation date |  | Date of operation | Date |  |  |
Operation type | Â | Type of the operation | Categorical | [RALRP; laparoscopic radical; ORPR; other] | (97.8) | |
Gleason primary score | Â | Gleason primary score at operation | Numeric | Â | 96.4 | |
Gleason secondary score | Â | Gleason secondary score at operation | Numeric | Â | 96.4 | |
Gleason tertiary score | Â | Gleason tertiary score at operation | Numeric | Â | 10.5 | |
Gleason total score | Â | Gleason total score at operation | Numeric | Â | 96.4 | |
Extraprostatic invasion | Â | Extraprostatic invasion flag | Categorical | [Yes; no] | 97.7 | |
Perineural invasion | Â | Perineural invasion flag | Categorical | [Yes; no] | 97.7 | |
Lymphovascular invasion | Â | Lymphovascular invasion flag | Categorical | [Yes; no] | 99.1 | |
Post- surgery pathology T | Â | Post-surgery pathology T stage | Categorical | [TX (cannot be assessed);T0; T1; T1a; T1b; T1c; T2Â l; T2a; T2b; T2c; T3; T3a; T3b; T4; T4a; T4b]- T4b | 97 | |
Post- surgery pathology N | Â | Post-surgery pathology N stage | Categorical | [NX (cannot be assessed); N0; N1; inconclusive] | 96 | |
Seminal vesical invasion | Â | Seminal vesical invasion flag | Categorical | [Yes; No] | 95.7 | |
Margin status | Â | Pathological margins status | Categorical | [Present; absent; abuts margin; equivocal] | 96.5 | |
ADT | Type of treatment | Â | Type of hormones prescribed | Categorical | [Chemical; surgical] | NÂ =Â 2734 (99.7) |
Start date | Â | Start date of hormones treatment | Date | Â | 100 | |
Class | Â | Type/class of hormones | Categorical | [Palliative; adjuvant] | 100 | |
Chemotherapy | Chemo agent | Â | Chemotherapy treatment flag | Categorical | [Yes; no] | NÂ =Â 70 (100) |
Chemo start date | Â | Start of chemotherapy treatment | Date | Â | 100 | |
Other treatment | Other treatment type | Â | Â | Categorical | [AS; WW; No treatment] | NÂ =Â 2602 (100) |
Other treatment date |  |  | Date |  | 15 (VIC–NA) | |
PSA | Â | Â | Other treatment type | Â | Â | Â |
 | Additional/subsequent/secondary treatment type |  | Date of other/additional treatment | Categorical | [AA; ADT; Brachytherapy; chemotherapy; EBRT; HDR; LDR; RALRP; low dose agonists; ORRP; other; recent biopsy; WW] | N = 12,039 (100) |
 | Treatment group | Treatment group derived from treatment type | Categorical | [Surgery; radiation therapy; hormones; AS/WW; other; unknown] | 100 | |
Treatment date | Â | Treatment date | Date | Â | 100 | |
PSA available | Â | PSA available flag | Categorical | [Yes; no] | 100 | |
PSA date | Â | Date of PSA taken | Date | Â | 95.3 | |
PSA value | Â | PSA value at treatment | Numeric | Â | 94.5 |